Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDKAL1 gene variants affect the anti-TNF response among Psoriasis patients.

International immunopharmacology - 1 Dec 2015

Coto-Segura Pablo, Batalla Ana, González-Fernández Daniel, Gómez Juan, Santos-Juanes Jorge, Queiro Rubén, Alonso Belén, Iglesias Sara, Coto Eliecer

Abstract excerpt

The heterogeneous response to anti-TNF biological drugs among Psoriasis (Psor) patients might be explained by gene variants linked to the risk for Psor. Common variants in the CDKAL1 gene have been associated with the risk of developing Psor. Our hypothesis was that these variants could also influence the response to anti-TNFs among Psor-patients. A reduction of at least 75% in the Psoriasis area and severity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Cyclin-Dependent Kinase 5

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Frequency

Share to Polymorphism, Single Nucleotide

Share to Psoriasis

Share to Treatment Outcome

Share to tRNA Methyltransferases

Source

Identifiers

PMID: 26563541
DOI: 10.1016/j.intimp.2015.11.008

Genes

CDKAL1
TNF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDKAL1 gene variants affect the anti-TNF response among Psoriasis patients.PMID 26563541Read ↗

Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population.Semantic proximity Read ↗

IL17RA gene variants and anti-TNF response among psoriasis patients.Semantic proximity Read ↗

New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.Semantic proximity Read ↗

Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe PsoriasisSemantic proximity Read ↗

Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs.Semantic proximity Read ↗

Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.Semantic proximity Read ↗

Genetic prediction of the effectiveness of biologics for psoriasis treatment.Semantic proximity Read ↗

Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis.Semantic proximity Read ↗

Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis.Semantic proximity Read ↗

Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated ReviewSemantic proximity Read ↗

Exploring pharmacogenetic variants for predicting response to anti-TNF therapy in autoimmune diseases: a meta-analysis.Semantic proximity Read ↗

A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 Agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.